• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

    5/7/25 8:26:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email

    The Company Intends to Request a Review of the Delisting Determination

    CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC ("NYSE American") stating that the NYSE Regulation has determined to commence proceedings to delist Palatin's common stock. The notice, issued under Section 1003(f)(v) of the NYSE American Company Guide, cites the low selling price of Palatin's common stock as the basis for delisting.

    Palatin Technologies, Inc.

    As a result, trading of Palatin's common stock on the NYSE American has been immediately suspended, and the shares will transition to the OTC Pink Market under the ticker symbol "PTNT" beginning on May 8, 2025.

    Palatin intends to appeal the delisting decision, although there can be no assurance that any such appeal will be successful. The Company has until May 14, 2025 to appeal the NYSE American's decision.

    "We are disappointed with the delisting determination," said Carl Spana, Ph.D., President and CEO of Palatin Technologies. "We continue to believe the Company has valuable assets and the actions of NYSE American will in no way deter our commitment to advance our business plan and increase stockholder value."

    Forward-looking Statements

    Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the transition of the Company's common stock to the OTC Pink Market and the Company's appeal of the NYSE American's delisting determination, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-technologies-announces-transition-to-otc-pink-following-nyse-american-delisting-notice-302449397.html

    SOURCE Palatin Technologies, Inc.

    Get the next $PTN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive VP and CFO/COO Wills Stephen T sold $8,274 worth of shares (4,999 units at $1.66), decreasing direct ownership by 2% to 235,456 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      8/2/24 5:01:24 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP and CFO/COO Wills Stephen T covered exercise/tax liability with 16,171 shares, decreasing direct ownership by 6% to 240,455 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      7/31/24 4:31:03 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Spana Carl covered exercise/tax liability with 24,428 shares, decreasing direct ownership by 9% to 261,459 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      7/31/24 4:31:01 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    SEC Filings

    See more
    • SEC Form 424B4 filed by Palatin Technologies Inc.

      424B4 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/8/25 5:27:16 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/8/25 5:26:19 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Palatin Technologies Inc.

      EFFECT - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

      5/7/25 12:15:09 AM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PTN
    Financials

    Live finance-specific insights

    See more
    • Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

      4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

      4/11/24 4:45:17 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Palatin Technologies with a new price target

      HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously

      11/24/21 6:07:03 AM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

      Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

      2/13/25 7:30:00 AM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

      CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

      2/10/25 4:00:00 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

      Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a

      11/14/24 7:30:00 AM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

      Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and functionTopical and systemic administration options enable potential for earlier intervention than current therapiesResults support the continued development of PL9654 and PL9655 for the treatment of diabetic retinopathy (DR)CRANBURY, N.J., May 9, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new

      5/9/25 7:30:00 AM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin Technologies Announces Closing of Reduced Public Offering

      Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the "Series F Warrants"), Series G warrants to purchase up to 7,324,119 shares of common stock (the "Series G Warrants"), and Seri

      5/8/25 10:19:00 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025

      Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution. Responder analyses demonstrate statistically significant symptom resolution across multiple endpoints in PL9643-treated patients compared to placebo. 6 of 13 symptom endpoints reached statistical significance (p<0.05).This level of symptom clearing has not been demonstrated by any currently approved dry eye disease therapy.Symptom resolution was observed as early as two weeks and continued through week 12 without plateau.PL9643 significantly improved clinical signs for staining measures, indicating potential to protect the ocular surface.PL9643 was well tolerated, with advers

      5/8/25 4:39:00 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Palatin Technologies Inc. (Amendment)

      SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

      2/14/24 2:55:16 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Palatin Technologies Inc.

      SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

      2/14/23 1:19:39 PM ET
      $PTN
      Biotechnology: Pharmaceutical Preparations
      Health Care